(Q56892367)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

title

Combination Immunotherapy in Non-small Cell Lung Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference

non-small-cell lung carcinoma

1 reference

Melina E Marmarelis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

Charu Aggarwal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

language of work or name

English

0 references

publication date

8 May 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

published in

Current Oncology Reports

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

page(s)

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo

26 March 2020

cites work

1 reference

12 December 2020

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

1 reference

12 December 2020

Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.

1 reference

12 December 2020

Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells

1 reference

12 December 2020

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

1 reference

12 December 2020

Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin.

1 reference

12 December 2020

Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape

1 reference

12 December 2020

The blockade of immune checkpoints in cancer immunotherapy

1 reference

12 December 2020

Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response

1 reference

12 December 2020

VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer

1 reference

12 December 2020

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

12 December 2020

Structure and T cell inhibition properties of B7 family member, B7-H3.

1 reference

12 December 2020

Bevacizumab plus ipilimumab in patients with metastatic melanoma

1 reference

12 December 2020

Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.

1 reference

12 December 2020

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

12 December 2020

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data

1 reference

12 December 2020

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

1 reference

12 December 2020

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

12 December 2020

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

1 reference

12 December 2020

TIGIT: A Key Inhibitor of the Cancer Immunity Cycle

1 reference

12 December 2020

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

1 reference

12 December 2020

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy.

1 reference

12 December 2020

CAR T-cell therapy for lung cancer and malignant pleural mesothelioma

1 reference

12 December 2020

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

1 reference

12 December 2020

1 reference

12 December 2020

Epacadostat Shows Value in Two SCCHN Trials

1 reference

12 December 2020

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

1 reference

12 December 2020

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

1 reference

12 December 2020

10.1007/S11912-018-0697-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29740718%20AND%20SRC:MED&resulttype=core&format=json

26 March 2020

1 reference